⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
prnewswire.com
JNJ
Rybrevant (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
JNJ
HALO
Zabdeno (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
JNJ
Tecvayli (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
JNJ
Bladder Cancer Patients Report Delayed Diagnosis and Gaps in Support
globenewswire.com
JNJ
FER
URGN
Pharmaceuticals, Biotechnology and Diagnostics M&A Agreements Report/Directory 2026: Analyse 2,500+ Deals Signed Since 2021 - Company A-Z, Therapeutic Area, Technology Type, and Industry Segment
globenewswire.com
JNJ
NVS
EcoVadis and Watershed partner to close the Scope 3 data gap
prnewswire.com
JNJ
JPM
FDX
V
Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia
globenewswire.com
MRK
JNJ
GOOG
Demande d’autorisation de mise sur le marché de TECVAYLI®▼ (teclistamab) en monothérapie soumise à l’EMA pour le myélome multiple en rechute ou réfractaire après au moins une ligne de traitement antérieure
globenewswire.com
JNJ
Antrag bei der EMA für die TECVAYLI®▼ (teclistamab)-Monotherapie zur Behandlung des rezidivierten/refraktären multiplen Myeloms nach mindestens einer vorherigen Therapie eingereicht
globenewswire.com
JNJ